Podcasts about Stipe

TIMBO SUGA SHOW X CHAEL!Tim "Red Hawk" Welch is joined by Suga Sean O'Malley, the legend Joe "Diesel" Riggs, and "The West Linn Gangster" Chael Sonnen! The boys talk the UFC White House card, Gina vs Rhonda on Netflix, RAF, Riggs vs Diaz and more! Later on the boys are joined by Bryce Meredeth to preview his BIG match at RAF!⚡️Check out PrizePicks! Sign up with code "TIMBO" to play $5 and WIN $50 INSTANTLY Click https://link.prizepicks.com/LME0/TIMBO♠️ Check out Spade! Use Code: TIMBOSPADE10 FOR 10% OFF!!https://www.amazon.com/stores/SPADE/page/91C86242-444D-487E-9D63-3FBB1503187F?ref_=ast_blnTimecodes: 00:00 Prize Picks CODE: TIMBO00:52 Welcome Uncle Chael!1:38 Rousey vs Carano BREAKDOWN6:08 Sug vs Yadong BREAKDOWN8:08 White House Card FINALIZED?!11:56 Strickland vs Fluffy BREAKDOWN 12:47 Riggs Gun Story Pt. 113:47 Spade CODE: TIMBOSPADE1014:22 Riggs Gun Story Pt. 214:35 Strickland vs Fluffy Continued 16:40 RAF 06 BREAKDOWN19:30 CAIN vs STIPE!?22:47 Deen The Great AWFUL Week23:13 Riggs Thanks Uncle Chael24:42 Chael Got SCAMMED 29:01 Yan Back Surgery Update30:58 Sonnen Wrestling Lineage Continues32:31 Riggs vs Nick Diaz Story38:07 Welcome Bryce Meredith!38:21 Diesel Making Major Life Changes…?41:11 Deen The Great Gets CHECKED Pt. 245:05 Joe Fights A ROOSTER57:18 Curt Fights A Ninja Warrior51:23 Matan Pod Recap54:39 Diesel To Check Into Anger Management …55:10 White House Card Pt. 256:25 Epstein Files 58:47 Strickland vs Fluffy Pt. 21:00:36 Bryce's Wrestling Camp 1:03:38 Mokaev OUT of RAF 061:13:00 Cejudo vs Faber BREAKDOWN1:13:55 Tsarukyan vs Poullas BREAKDOWN1:14:41 Carr vs Jenkins BREAKDOWN1:15:08 Mendes bs Henderson BREAKDOWN 1:20:47 Confidential Sneak PeekCheck out the Patreon! Years of Content / Confidential SHOW Weeklyhttps://www.patreon.com/redhawkacademyBest plunges in the gamehttps://www.coldtub.comcode: TIMBO at checkout for 500$ off!Outdoor shower!https://plunge.com/products/plunge-outdoor-showerSnapchathttps://www.snapchat.com/add/timwelchmt?locale=en-US

In which Robert & Amy celebrate the New Year and join the movement to make 2026 The Year Of Selfishness! Celebrate your fine self, and make 2026 Your Best Year Yet! Reliving The Me Decade in a year. Looking back on 2025, and looking forward to a new year of virtues, values, and living large! Also, Pooh, Braille, Stipe, how to think about news, trends, war, and general mayhem in the culture. It's the 1980's All Over Again! Let's relive the Me Decade!

Welcome to the BCJ Podcast, brought to you by Holy Grail and broadcast from Cincy Light Studios on bearcatjournal.com! Join Chad Brendel and David Simone as they have a quick chat with Associate AD Zach Stipe, and then dive into a game-by-game breakdown of the Cincinnati Bearcats 2025 season with fall camp wrapping up, attempting to predict the outcome of the upcoming season. Get ready for the season opener against Nebraska at Arrowhead—join the BCJ watch party at The Holy Grail on Sept. 28th for Cincy Light swag and specials! #Bearcats #Big12 Like and subscribe for more Bearcats updates and visit bearcatjournal.com! Time Stamps are brought to you by Turtle's Brew! Enjoy zero-sugar, zero-carb, gluten-free bourbon-infused sweet tea with 6% ABV in flavors like cherry lime, raspberry peach, orange vanilla, lemonade tea, and strawberry mint. Available at over 50 locations in Greater Cincinnati and 100+ across Ohio. Find your nearest spot at turtlesbrew.com! 0:00 - 29:00 Associate AD Zach Stipe 29:00 - 1:43:05 Prediction Party

R.E.M. put out a multitude of hits in college, modern, and alternative rock genres in the 80's and 90's.  By the time that Around the Sun, the group's 13th studio album was released, the band was experiencing changes in personnel and struggles with focus.  Drummer Bill Berry retired in 1997 and was replaced by Bill Reiflin.  While Reiflin would be the regular percussionist for the band until their dissolution in 2011, he would not be considered a member of the band like Peter Buck (guitar), Mike Mills (bass, keyboards), or Michael Stipe (vocals).  From a commercial standpoint the album was a success, going to number 13 on the Billboard 200 in the US, and topping the album chart in the UK.  However, critical reviews were more negative, and the band members would agree over time with Stipe and Mills stating that the album lacked focus.  Peter Buck was more critical, stating that the album shows that the band was bored with the material.  Many consider this the worst R.E.M. studio album the group produced. However, with the benefit of hindsight we think this album is due for a second look.  The songs are more adult-oriented than the bands hits from prior decades, yet maintain the distinctive R.E.M. sound.  There is a cleaner production on this album and clearer lyrics.Rob brings us a great debut folk rock album in this week's podcast.Leaving New YorkThe lead off track was also the lead single from the album.  It reached number 5 on the UK singles chart, making it the eleventh and last top-10 REM single in that country.  However, it was not heavily promoted and failed to crack the US Billboard Hot 100 chart, becoming the first US single from an REM studio album not to chart since 1985.  It has a somber tone.WanderlustThis was the fourth and final single from the album, and utilizes a complex time signature of 4/4 time in the verses and 7/4 in the chorus.  The title references the desire to travel, and not remain in one place for very long.  "I got my signals crossed.  It's overwhelming me because I'm all alone and I cant get back - get back with my wanderlust."AftermathThe second single from the album portrays a woman living in a daze after a breakup.  Overwhelmed by ruminations, she overfeeds the cat and underwaters the plants.  It went to number 15 on the US alternative rock chart and number 41 on the UK singles chart.  around the sunThe album contains a title track - a rarity on REM albums.  It begins with a soft acoustic guitar leading into pensive lyrics.  "Hold on world, 'cause you don't know what's coming.  Hold on world, 'cause I'm not jumping off.  Hold on to this boy a little longer, take another trip around the sun." STAFF PICKS:1985 by Bowling for SoupBruce starts the staff picks with a song about a middle-aged woman thinking about how things have changed since her glory days in 1985.  It is a cover song originally done by pop punk band SR-71, but made famous by the Bowling for Soup version.  It went to number 23 on the Billboard Hot 100, and number 5 on the Adult Top 40.  Float On by Modest MouseLynch brings us a track that songwriter and band founder Isaac Brock says was consciously written to feel more positive than some of his previous work.  The lyrics are stoic - not getting caught up in the bad things, because good things are around the corner.  "Alright, already, we'll all float on."I Go Back by Kenny ChesneyWayne's flips the script on us by bringing a country song into the mix, but with lyrics that talk about listening to rock songs in the past.  With references to the Steve Miller Band, Billy Joel, Sunday church, Sunday lunch, and the death of a High School friend, Chesney recounts days gone by. COMEDY TRACK:Goofy Goober Rock by SpongeBob SquarePants"The SpongeBob SquarePants Movie" was released around this time, and included this parody of a Twisted Sister song.   Thanks for listening to “What the Riff?!?NXTGen”NOTE: To adjust the loudness of the music or voices, you may adjust the balance on your device. VOICES are stronger in the LEFT channel, and MUSIC is stronger on the RIGHT channel.Please follow us on Facebook https://www.facebook.com/whattheriffpodcast/, and message or email us with what you'd like to hear, what you think of the show, and any rock-worthy memes we can share.Of course we'd love for you to rate the show in your podcast platform!**NOTE: What the Riff?!?NXTGen does not own the rights to any of these songs and we neither sell, nor profit from them. We share them so you can learn about them and purchase them for your own collections.

DC IS FINALLY HERE!"Mighty" Demetrious Johnson welcomes former UFC heavyweight & light heavyweight champion Daniel "DC" Cormier!⚡️ Shoutout to SUSHISAMBA for hosting 'The MightyCast'! Located in the Palazzo in Vegas, my favorite restaurant in Vegas! https://www.sushisamba.com/locations/usa/las-vegasTimecodes0:00 Intro0:57 PrizePicks Code MIGHTYCAST1:43 Shoutout SUSHISAMBA!!2:11 DJ is Going to Dagestan?4:12 DC Calls Out DJ

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

LIVE FROM ENGLAND w/ TOM ASPINALL!"Mighty" Demetrious Johnson is joined by the UFC interim heavyweight champion Tom Aspinall LIVE from ENGLAND!Timecodes0:00 Intro 1:05 PrizePicks Code MIGHTYCAST 1:51 Welcome Tom Aspinall!  2:00 Tom's Dad is His Coach and Manager 3:13 This Pod was a Long Time Coming… 4:05 This is DJ's First Trip in Europe 4:57 DJ and Tom Linked Up in the Middle of Nowhere 5:55 Tom's Intro to Martial Arts 7:11 Tom's Athletic Background  7:30 Why Tom Gravitated Towards MMA as a Kid 8:26 Tom's First Martial Art 10:26 Tom's Extensive Amateur MMA Career 11:48 The Secret to Tom's Elite Technique  12:49 Tom's Dynamic Movement  14:59 Ridge Code MIGHTYCAST 16:07 Tom's Dad has Always Been His Coach 16:59 Tom Almost Quit MMA?! 18:04 Will Tom Coach His Kids in MMA? (UK Fighter Pay Struggles) 20:27 Why MMA is Great for Young Men 21:10 How to Make GREAT Money in MMA 22:31 Why MMA Fighters Get Taken Advantage of 24:30 Tom's Rise from Amateur to UFC Fighter  25:53 Sparring with Tyson Fury (Go Pro in Boxing) 26:41 How the UFC Discovered Tom/Cage Warriors Rise 28:48 Tom was Hesitant to Join the UFC Contract? 32:15 Tom's Dominant Start to His UFC Career 34:08 Tom's First Main Event Against Volkov in London 35:30 Tom's World Class Heavyweight Gym 36:58 Tom has the Shortest Average Fight Time in UFC History 38:05 Who Runs Tom's Training Camp? 39:51 How Tom Prepares for Fights 41:10 Tom has NEVER Been Past the 1st Round 43:50 Tom's Fighting Mindset  45:57 Should the UFC Ban Weight Cutting? 48:52 Tom is a Natural Heavyweight 49:37 Tom's Big Advantage at Heavyweight 50:23 Pereira vs Aspinall BREAKDOWN 51:59 Fighting at Heavyweight is Easy? 53:43 Tom's In and Out Footwork 55:34 When is Tom vs Jon Jones Happening? 1:02:25 Tom is Leveling Up Big Time Out of Camp  1:03:38 When Does Tom Want to Fight Jones? 1:05:41 How Often Does Tom Spar?  1:07:25 How Often Does Tom Spar?  1:07:52 What is Better: Technical or Hard Sparring?  1:08:26 How Often Does Tom Spar? 1:10:04 Hard Sparring is Not Worth It… 1:13:42 Tom's Hilarious YouTube Channel 1:16:41 Tom Trains with Eddie Hall 1:19:19 Could DJ Beat Eddie Hall in MMA? 1:20:03 How Tom Spent His First Big Check 1:22:33 How Tom Spent His Last Big Check 1:23:38 How to Support Tom  1:24:31 Why Hasn't Tom vs Jon Jones Happened? 1:27:29 Stipe vs Jones Shouldn't Have Happened? 1:28:59 Tom's New Deal with Champion  1:29:42 DJ Gives Tom His Flowers  1:32:06 MightyRecap! 1:32:22 Tom is Such a Nice Guy 1:33:02 DJ Loves that Tom's Dad is His Coach 1:33:18 Tom's Movement Breakdown 1:33:56 The UFC is Doing Tom Dirty with the Jones Fight… 1:35:07 Jones vs Tom BREAKDOWN 1:36:45 Why Hasn't Jones vs Tom Happened?  1:38:19 Is Jones Ducking Tom?! 1:39:06 Stipe vs Jones Should Not Have Happened? 1:42:04 Jon Jones is Doing Everything on Purpose?  1:42:46 SIGNED DJ AND TOM GLOVE GIVEAWAY!! 1:43:33 Will Tom vs Jones Happen? 1:44:30 Is Jones Still the GOAT if He Ducks Aspinall?  1:47:10 Can the UFC Please Promote Fights Again  1:48:02 Tom Can Be a SuperstarProduced/edited by Michael Wonsover (@mwonsover on IG/Twitter)Edited by Nick Pappas (@nick_pappas44 on IG)⚡️1st Phorm

Send the show a text message!In this episode of the Space Between podcast, host Renae Lipsmeyer interviews Jennifer Stipe, who shares her unique journey as a fan of the Dave Matthews Band. From her gardening adventures to starting a business during challenging times, Jennie reflects on how music has shaped her life and provided a sense of community. She recounts her early experiences with the band, the impact of their music on her personal growth, and the connections she formed with others who share her passion for the band. The conversation highlights the transformative power of music and the importance of taking chances in life. Jennie shares her profound connection to the Dave Matthews Band, detailing how their music served as a lifeline during her turbulent teenage years marked by addiction and family struggles. She recounts her journey to see the band live, the emotional significance of their concerts, and a pivotal moment when she received a tattoo drawn by Dave Matthews himself, symbolizing her gratitude for the impact his music had on her life. Jennifer Stipe reflects on the surreal moment of meeting her hero, the impact of music during challenging times, and the importance of community and vulnerability in sharing personal stories. The discussion also touches on the science behind music and its therapeutic effects on mental health, emphasizing how music can serve as a powerful tool for healing and connection.#DMB #davematthewsband #podcast  Support the show

In this episode of Omni Talk's Ask an Expert series, Chris Walton and Anne Mezzenga talk with Stipe Galic, VP of Business Development & Marketing at TGW, to demystify the complexities of returns in today's omnichannel retail world. From cost savings to faster reshelving, Stipe walks us through how automation, flexible software, and a unified DC setup are transforming how retailers like Urban Outfitters manage inventory and returns. Key Moments: 1:05 – Stipe's journey from mechanical engineer to automation leader at TGW 4:59 – Why returns are such a thorn in omnichannel fulfillment 7:00 – Real-time processing of returns with mixed-SKU totes 10:00 – How software decides between single-SKU and return stock 14:36 – Case study: High-end fashion retailer consolidating DC operations 19:56 – Cutting return costs nearly in half through automation 22:00 – “Bridge vs. Ferry” analogy on warehouse responsiveness 24:35 – Seamless integration > cutting-edge tech: the new mindset Music by hooksounds.com *Sponsored Content*

She played Danny's equal when it came to all things cleanliness... It's Debra Stipe, aka Cindy! Did you know that originally, Cindy and Danny were supposed to get married?! Debra tells us exactly why she turned down the opportunity... Let's just say, we would've been rooting for a Danny + Cindy marriage!! Hear all about Debra's experience on set and what it was like working with the Full House cast and crew! It's all right here on How Rude, Tanneritos! See omnystudio.com/listener for privacy information.

In 1948, at the age of 21, Gene Stipe was elected to the Oklahoma State House of Representatives representing Pittsburgh County, making him the youngest person elected to the state legislature. Stipe won a senate seat in 1956 and served for forty-eight years, making him the longest-serving Oklahoma State Senator.   Gene had a reputation as an excellent trial lawyer and took the lead in some important Oklahoma court cases.On January 1st, 2000, Gene published the book A Gathering of Heroes, featuring stories of many Oklahomans. Some of the heroes he talked about included former U.S. Senator Robert Kerr, Judge Luther Bohanon, and Lloyd Rader.The book is still available on Amazon.  Gene Stipe was 85 when he died on July 21st, 2012.When John Erling was with KRMG radio, he interviewed Gene about the book in 2000, and you can hear the interview now on the podcast and oral history website VoicesOfOklahoma.com.

R.E.M. considered themselves missionaries against the prevailing pop culture – no solos, no old-school stagecraft, no printed lyrics, no lip-syncing, no hard-sell videos, no obvious leader – and mapped out a whole new route to international success. Peter Ames Carlin, whose books include biographies of Springsteen, Brian Wilson and Paul Simon, talks to us here about ‘The Name of this Band is R.E.M.', what they pioneered and how it rearranged the rock and roll furniture. Which involves … … why their Letterman Show was a statement of intent. … “rather than bending to the mainstream, they did what they wanted ‘til the mainstream bent to them.” … where you can see “the R.E.M. model” - from Sleater-Kinney to Taylor Swift. … when ‘Mike Stipe' became Michael. … Stipe's first TV appearance, dressed as Frank-N-Furter at a Rocky Horror Show screening. … why rock critics connected with them.  … the strategies they share with U2, Radiohead and Coldplay.  … “Springsteen = Elvis + Dylan”. … what was in the water in Athens, Georgia, that produced such unconventionalacts - R.E.M., the B-52's, Pylon, Love Tractor. … their ‘straight' but supportive parents – Stipe's dad in the military, Mills' dad a marine helicopter pilot. … how R.E.M. “channelled popular culture”. … their pioneering approach to record deals, royalties, videos, mixing and song-writing. … and which of them most wants a reunion. Order ‘The Name Of This Band Is R.E.M.' here:https://www.amazon.co.uk/Name-This-Band-M-Biography/dp/0385546947Find out more about how to help us to keep the conversation going: https://www.patreon.com/wordinyourear Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.

MARCUS IS BACK!Sub to Marcus YouTube!  @Marcus_Maniac_McGhee  Follow Marcus on IG @maniac_mcgheemmaOn this week's episode of the Red Hawk Recap, Tim “The Red Hawk” Welch is joined by Joe Diesel Riggs and fresh off his huge win at UFC 309, the #14 ranked bantamweight in the world, Marcus McGhee! The boys go deep on Marcus' Big Win, who's next, Jones vs Stipe, is Jon Jones ducking Tom Aspinall, Mike Tyson vs Jake Paul and more!♠️ Check out Spade! Use Code: TIMBOSPADE10 FOR 10% OFF!!https://www.amazon.com/stores/SPADE/page/91C86242-444D-487E-9D63-3FBB1503187F?ref_=ast_blnTimestamps:0:00 Intro0:29 Spade! CODE TIMBOSPADE10!1:11 Tyson vs Paul Trip Recap3:26 UFC on Netflix Next Year?!4:14 Marcus' BIG WIN Over Jonathan Martinez at UFC 309!6:57 Calf Kicks Hurt SO Bad…8:18 How Marcus Survived the Final 2 Minutes vs Martinez9:25 How to Stay Composed in a Fight11:15 Marcus' Walk Around Wait (BIG 135er)14:22 Weight Cutting Used to Be SKETCHY15:41 Does Weight Cutting Impact Your Chin?16:30 Weight Cuts are BRUTAL/Proper Weight Cutting17:46 Tim's Problem with the UFC…18:03 The Boys Spark Up!18:56 Marcus is OFFICIALLY Ranked19:48 Does Marcus Let His Kids Watch His Fights?20:08 Riggs Set Marcus Up?!(Local Fights)21:08 Joe Peed on People's Feet After Fights?!21:30 Who is Next for Marcus?!25:43 Don't Shield Your Kids from the World…26:47 Addiction in Marcus' Family28:41 Are Fathers or Mothers More Important for Kids?29:46 Is it Better for Unhappy Parents to Stay Together?31:52 Relationships are SO Hard32:46 Can Bo Nickal Beat Khamzat?!36:49 Oliveira vs Chandler BREAKDOWN38:41 Jones vs Stipe BREAKDOWN39:37 The Hardest Hitting Shot in MMA41:01 Jones vs Aspinall WHO Wins?!42:02 Will Jones Fight Aspinall?44:52 Crazy NFL vs UFC Reveune Stats47:50 Crypto is PUMPIN Right Now…49:00 Marcus & Tim Buying Food Trucks?49:55 The Boys Craziest Street Fight Stories56:42 Marcus' Unique Recovery Routine58:57 Elite MMA Athletes 59:10 Marcus is JACKED1:00:21 Marcus Teaches the Boys Wing Chun

On episode 200, the boys talk about Tyson vs Paul and Jones vs Stipe. They dive into the latest films they watched. Zeke's 5th birthday and Renato's cooking.

MMA GURU IS BACK! On the latest episode of "MightyCast", Demetrious Johnson is joined by the one & only MMA Guru to recap UFC 309, Jones vs Aspinall, & more! Timestamps Timestamps 0:00 Intro   0:52 PrizePicks CODE MIGHTYCAST!   1:32 Welcome MMA Guru!   2:31 MMA Guru is an ELITE Detective   3:54 Jones vs Stipe REACTION   6:24 Guru is Happy Jones Didn't Fight Aspinall?   9:31 DoorDash CODE MIGHTY 2024!   10:28 VIIA HEMP CODE MIGHTY!   11:45 Stipe's Performance Against Jones   12:32 Is Jones Ducking Aspinall?   16:46 Why Does Dana Glaze Jon SO Much?   18:00 Jon HAS TO Fight Aspinall Next?   22:07 The Heavyweight Division is BAD…   24:54 Guru's HOT TAKE on Jones Positive Steroid Tests   26:30 What to Do if Jones Won't Fight Aspinall   27:16 Rico Verhoeven to the UFC?!   29:17 Guru's HOT TAKE on Jones Positive Steroid Tests PT. 2   31:19 DJ's Take on Jon's Positive Steroid Tests   33:50 Who is Guru's GOAT of MMA   35:35 Deep Dive into Jones' Positive Tests   37:13 UFC Stars Failing Drug Tests   44:24 Fans Forget Fighters Used to be JUICED UP…   48:06 UFC Stars Failing Drug Tests PT. 2   52:05 The UFC is Going After Guru?   54:26 The Secret to Guru's YouTube Success   54:58 Oliveira vs Chandler BREAKDOWN   56:23 Chandler Cheated Against Charles?!   58:20 Chandler vs McGregor BREAKDOWN   58:41 Chandler's NEW Fight Style   1:02:16 Who is Next for Oliveira/Chandler?   1:07:53 Chandler vs Holloway Next?!   1:08:26 Tyson vs Paul/Till vs Fury REACTION   1:09:38 Jake Needs to Fight a REAL Opponent…   1:12:05 Where to Follow Guru(He's a Decent Guy)   1:13:29 MightyRecap!   1:13:40 DJ's Reaction to Jon's Failed Tests   1:14:55 What DJ Wants Next for Jones/Pereira/Aspinall   1:21:02 What Deems a Fighter as “The Goat”   1:24:56 Will Jones vs Aspinall Happen? Produced/Edited by Michael Wonsover (@mwonsover on IG/Twitter) Edited by Nick Pappas (@nick_pappas44 on IG) ⚡️ PrizePicks: Sign up with code "MIGHTYCAST" to play $5 and WIN $50 INSTANTLY https://prizepicks.onelink.me/ivHR/MIGHTYCAST If you're +21, try VIIA Hemp today and use code MIGHTY to save 15% https://bit.ly/viiamighty ⚡️ 1st Phorm: Check out 1st Phorm at https://1stphorm.com/mightycast ★ Merch: https://shopmighty.com ♦ Twitter: https://twitter.com/mightymouse/ ♦ Instagram: https://www.instagram.com/mighty/ ♦ Discord: https://discord.gg/mightysquad ♦ My Quantum Bars: https://quantumsquares.com/ Promo Code: MIGHTYGAMING10 ♦ My Cold Therapy: https://icebarrel.com/ Promo Code: MIGHTY

Liga Combate en las redes sociales: Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.twitter.com/ericaiexander⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Segundo Canal:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UC4o9ZJOU60cS984XcgHndPA⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.instagram.com/ericalexander.mma⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/LigaCombate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Whatsapp: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://whatsapp.com/channel/0029VaBIOBU8PgsEAWx47h0U⁠ --- Support this podcast: https://podcasters.spotify.com/pod/show/conexionmma/support

Brendan Schaub recaps UFC 309 Jon Jones vs Stipe Miocic, Jake Paul vs Mike Tyson and Gamebred BKMMA 8 and talks people calling Jake Pauls fake, Stipe looking like he didn't even want to fight, how Jon Jones being undefeated for this long is the most impressive thing in all of sports, however, he's not sure if this version of Jones can beat Tom Aspinall, and how Tom will never be the greatest if Jon retires. Also, current events including Mikey Musumeci signing with the UFC, Nick Diaz out of his fight with Vicente Luque, Tommy Fury vs Darren Till in boxing, Kron Gracie vs Bryce MItchell, Ian Machado vs Shavkat Rakhmonov, Colby Covington vs Joaquin Buckley and much more. Magnesium Breakthrough by BIOptimizers - Head over to bioptimizers.com/schaub and enter code Schaub at checkout to get discounts plus access to up to $100 in free gifts with purchase. DraftKings - Download the DraftKings Sportsbook app NOW and use code SCHAUBSHOW O'Reilly - http://oreillyauto.com/SCHAUB Progressive - https://www.progressive.com/ Sure Shot - https://sureshot.com/

What a wild weekend it was and MK is here to break it all down for you. BC and Luke are back in studio and kick-off the show by talking all things UFC 309. In the main event, Jon Jones made a dominant return from injury/layoff to retire Stipe Miocic via TKO3. In just his 2nd fight in 5 years and first in 18 months following surgery, Jones looked like a complete heavyweight threat. In what ways did BONY's destruction of Miocic add to his already GOAT-plated legacy?   After his destruction of Stipe, Jon Jones said he wants "f**k you money" to fight Tom Aspinall, but still prefers theAlex Pereira fight. From all of the fight week rherotic to Jones' post-fight reaction, do you now believe he will fight Tom Aspinall next and that the UFC pay him handsomely enough to accept it? In the co-main event, Charles Oliveira held off a furious Michael Chandler rally to secure possible title shot. At 35, how much of a threat does Charles Oliveira still appear to be in terms of regaining the UFC lightweight title?   Moving on to UFC 310, Luke and Brian react to the new card announcement, following Belal Muhammad's withdrawal and UFC's late replacements. And of course, we can't forget the boxing fight of the year as Jake Paul outpointed Mike Tyson in pointless, record-breaking Netflix main event. While it's easy for everyone to ask, in hindsight, "what did you expect" from a YouTuber and a 58-year-old, how much of a stain was it for boxing given the 65 million households watching globally that Tyson-Paul turned out to be nothing more than a scripted exhibition between friends? Given the controversy of Taylor-Serrano rematch, is there a market for a trilogy fight?  Learn more about your ad choices. Visit podcastchoices.com/adchoices

What a wild weekend it was and MK is here to break it all down for you. BC and Luke are back in studio and kick-off the show by talking all things UFC 309. In the main event, Jon Jones made a dominant return from injury/layoff to retire Stipe Miocic via TKO3. In just his 2nd fight in 5 years and first in 18 months following surgery, Jones looked like a complete heavyweight threat. In what ways did BONY's destruction of Miocic add to his already GOAT-plated legacy?  After his destruction of Stipe, Jon Jones said he wants "f**k you money" to fight Tom Aspinall, but still prefers theAlex Pereira fight. From all of the fight week rherotic to Jones' post-fight reaction, do you now believe he will fight Tom Aspinall next and that the UFC pay him handsomely enough to accept it? In the co-main event, Charles Oliveira held off a furious Michael Chandler rally to secure possible title shot. At 35, how much of a threat does Charles Oliveira still appear to be in terms of regaining the UFC lightweight title?  Moving on to UFC 310, Luke and Brian react to the new card announcement, following Belal Muhammad's withdrawal and UFC's late replacements.And of course, we can't forget the boxing fight of the year as Jake Paul outpointed Mike Tyson in pointless, record-breaking Netflix main event. While it's easy for everyone to ask, in hindsight, "what did you expect" from a YouTuber and a 58-year-old, how much of a stain was it for boxing given the 65 million households watching globally that Tyson-Paul turned out to be nothing more than a scripted exhibition between friends? Given the controversy of Taylor-Serrano rematch, is there a market for a trilogy fight?  Learn more about your ad choices. Visit megaphone.fm/adchoicesSee omnystudio.com/listener for privacy information.

Sean and Graeme talk Jones vs. Stipe, Aspinall's shadow over the week, James Webb, KSW, Ian Garry and more! Patreon.com/SevereMMAPodcast And now….. here's the podcast!

Im a huge fight fan, and this was one hell of a fight weekend, with Tyson vs Paul and Jon Jones vs Stipe, although tbh, the real standout of the weekend was Taylor vs Serrano. But something was really different about the whole thing. Rather than be all about the fights, politics were all over the place. So what does it all mean? and wth is happening with Twitch? Don't stress, let's look over the fight tape together. I got you covered, with Janaya Future Khan.

Join me as I review UFC 309 from a totals perspective. We review every total on the board and discuss the betting lines for each of them. Clint will provide his leans for betting over or under and try to give you an alternate way to bet the fight if you cant pick a side!Premium Home of Fight Bets on Winnable: https://www.winible.com/checkout/1363223394291568749?store_url=/hofpicks&a=7B0B14&interval=Week Promo Code: 309 for a 5 day free trial*Bet Openly*: https://app.betopenly.com/?s=dhmFight Numbers DFS & Betting Tools: https://t.co/4wymvWC47oJoin Nuke The House for incredible sports betting results across all sportshttps://nukethehouse.com/Promo Code: CLINT for a FREE WEEKNew Die Hard MMA Merch!!Check out the shop! https://die-hard-mma-podcast-merch.myspreadshop.com/allFollow Spectation Sports @SpectationNet for Regional MMAPromo Code: DIEHARD for 20% off your subscription https://spectationlink.com/DIEHARD

Welcome back to Lawn Chair Sports. This week the boys discuss a great weekend for fights. Jake Paul vs. Mike Tyson and Stipe vs. Jones. Shoutout to the Bold Gold Antelopes. They also make their week 11 predictions. Follow Samuel Douglas : https://www.instagram.com/thesamueldouglas/Follow Leezy Lee : https://www.instagram.com/leezylee23/Follow The Snake Pit : https://www.instagram.com/thesnakepitpodcast_/s

UFC 309: Jones vs Stipe, Tyson vs Paul Boxing, Recap of last few weeks of Fights and LFA event review

UFC 309 is finally here! DC and Chael are back talking Jones and Miocic. So has DC seen Jon Jones? Hear why it involves one of them taking a walk. Does Jones dismissing Tom Aspinall taint his legacy? Chael is all in on the new look Stipe, but can he get it done against the greatest to ever do it? See what Chael has to say. Michael Chandler returns to the octagon and hear who DC compares him too. It may surprise you. Plus, what's at stake for Charles Oliveira. And, the guys chat about undefeated rising star Bo Nickal.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

BOYS ONLY EPISODE!On this week's episode of the Red Hawk Recap, Tim “The Red Hawk” Welch is joined by Joe Diesel Riggs and Warlike. The boys go deep on Jones vs Stipe, is Jon Jones ducking Tom Aspinall, Mike Tyson's tough open workout, Chandler vs Oliveira and more!⚡️Check out PrizePicks! Click here: https://prizepicks.onelink.me/ivHR/TIMBO and use the code "TIMBO" for a 100% Deposit Match Up to $100♠️ Check out Spade! Use Code: TIMBOSPADE10 FOR 10% OFF!!https://www.amazon.com/stores/SPADE/page/91C86242-444D-487E-9D63-3FBB1503187F?ref_=ast_blnTimestamps:0:00 Intro0:30 PrizePicks! 1:06 Warlike and Tim's Bet2:01 Riggs Corned at the UFC Fights3:06 Riggs Ran into Mackenzie Dern4:27 Joe Started “Microdosing”5:13 Joe Got Kicked Off a Plane?!7:49 Joe Got Baked All Fight Week8:47 Carlos Prates is a BEAST9:33 The Best Way to Do Shrooms (Joe's Bad Trip)11:19 Bo Nickal vs Paul Craig BREAKDOWN13:40 Marcus McGhee vs Jonathtan Martinez BREAKDOWN15:27 Charles Oliveira vs Michael Chandler BREAKDOWN17:31 Jon Jones vs Stipe Miocic BREAKDOWN19:23 Jones is DUCKING Aspinall?!20:35 Matt Hamill on Beating Jon Jones20:59 The Boys are Going to Tyson vs Paul27:28 Elon Musk's DOGE28:27 Crypto is BOOMING29:03 Unwritten BJJ Rules For White Belts30:33 Why Does Warlike Think He is the Next MMA Guru?31:30 Would Riggs Assault Warlike?31:52 Post Nut Clarity Stories34:07 What is More Important Endurance or Strength?35:35 Advice for Kickboxing Tournament36:58 Riggs Family Update 39:14 Would Tim Let Schmitty Get Jumped?39:41 Tim vs Coyotes42:34 Tim is Doing Some Cat Shopping46:47 RFK Jr. vs the FDA48:44 Tommy Got a Fight!51:04 If the Boys Went to College What Would It Be For?52:55 Joe is Working on His Stutter53:48 Figuerdo vs Yan BREAKDOWN!54:51 Mike Tyson is in Trouble…

Watch the episode on YouTube - https://www.youtube.com/watch?v=2aioWoXHLe8 Follow The BradyBagz Show On Instagram: https://www.instagram.com/thebradybagzshow/ Learn more about SteadyPicks: https://www.steadypicks.com/

On this episode of The MMA Roasted Podcast, the gang previews Tyson vs. Paul and Jones vs. Stipe! You do NOT want to miss this one! GAME TIME! Take the guesswork of buying tickets with GAMETIME! Download the Gametime app, create an account, and use the code CLNS for $20 off your first purchase! Download Gametime TODAY! Learn more about your ad choices. Visit megaphone.fm/adchoices

Michael Bisping and Anthony Smith discuss everything UFC 309 from previews and predictions for every fight on the main card, all the biggest stories going into fight week including Jon Jones talking retirement or Periera if he gets past Stipe, what to expect out of Michael Chandler after his long layoff and more plus a look at Tyson vs Paul on Friday night, Carlos Prates dismantling Neil Magny inside of a round then calling for a top-ranked opponent plus so much more! This Episode Was Recorded On 11.11.24 Follow the show on social media: Twitter: https://twitter.com/BYMPod Subscribe on YouTube: https://bit.ly/3drq6ps Follow the hosts on social: Michael Bisping Twitter https://twitter.com/bisping Michael Bisping Instagram https://www.instagram.com/mikebisping/ Michael Bisping YouTube https://www.youtube.com/channel/UCDrG2_1TcVkXKXXsD6Kjwig Website https://gasdigitalnetwork.com/gdn-show-channels/believe-you-me/ Anthony Smith Twitter: https://twitter.com/lionheartasmith Anthony Smith Instagram: https://www.instagram.com/lionheartasmith/ Mike's debut book "Quitters Never Win" is available wherever books are sold, click here to get a copy! https://bit.ly/2V9ZqDk Follow the team on social: Brian MacKay Instagram: https://www.instagram.com/bmackayisright Brian MacKay Twitter: https://twitter.com/bmackayisright Mike Harrington Twitter: https://twitter.com/TheMHarrington Mike Harrington Instagram https://www.instagram.com/themharrington Mike Harrington YouTube: https://www.youtube.com/@themharrington Learn more about your ad choices. Visit megaphone.fm/adchoices

Luke Thomas helps preview the big Jon Jones return at UFC 309! What's Stipe's path to victory, is there one? Is Jones ducking Aspinall? Will Pereira really be next? What's Chander/Oliveira 2 gonna look like, is Bo Nickal ready for the deep end of 185 and more! Subscribe to Luke's channel and tune in for his live watch along! https://www.youtube.com/@UC2EuJ9xTs0XkDZI9YGx7QZA IF YOU WANT TO SUPPORT PLEASE SUBSCRIBE TO THE CHANNEL: http://bit.ly/2arsrDN Download the Saily app and use the code [submission] or go to https://Saily.com/submission to get an exclusive 15% off your first purchase. Don't forget to use code "SUBMISSION" at https://Manscaped.com for 20% AND FREE SHIPPING (Plus you're helping the show)  Get THE BEST VPN, NORDVPN TODAY! Get 4 months free and a special offer now: https://Nordpn.com/Submission   

MICHAEL CHANDLER IS BACK! On the latest episode of "MightyCast", Demetrious Johnson is joined by the one & only "Iron" Michael Chander ahead of his UFC 309 co-main event vs Charles Oliveira! ⚡️ Upgrade your wardrobe and save on @trueclassic at trueclassic.com/MIGHTY ! #trueclassicpod ⚡️ Go to BetterHelp.com/MIGHTYCAST to save 10% on your first month! ⚡️ PrizePicks: Sign up with code "MIGHTYCAST" to play $5 and WIN $50 INSTANTLY https://prizepicks.onelink.me/ivHR/MIGHTYCAST Timestamps 0:00 Intro 1:03 PrizePicks! 1:52 Welcome Michael Chandler! 2:16 Chandler has a Skin Care Routine?! (DJ's Secret Skincare) 4:24 Chandler vs Eddie Alvarez was a BANGER 7:30 Chandler's was VERY Active Before McGregor 9:22 Why Did Chandler Leave Bellator? 11:51 Better Help! 13:17 True Classic Tees! 16:17 Taking 2 Years Off Waiting for McGregor 21:55 Will Conor McGregor Ever Fight Again? 24:22 2 Years Off Helped Chandler? 26:44 Chandler's UNIQUE Strength and Conditioning Routine 33:48 Why Does Chandler Get Tired in Fights? 37:21 Chandler's Legendary Work Ethic 42:39 Tyron Woodley and Ben Askren Changed Chandler's Life 46:46 The KEY to DJ and Chandler's MMA Success 47:50 Chandler Told Paddy to Stop Getting Fat? 50:38 How to Create a Strong Work Ethic in Your Kids 54:23 How to Handle Losses 56:06 Chandler vs Charles Oliveira 2 BREAKDOWN 1:01:08 Chandler's Alter Ego 1:03:09 Chandler's Tequila Company 1:06:32 DJ's Experience with Edibles 1:10:08 Shoutout 1st Phorm! 1:10:38 Chandler's Thoughts on Bo Nickal 1:12:46 Jon Jones vs Stipe Miocic BREAKDOWN 1:14:05 Chandler's Nutrition Plan 1:16:23 Chandler has Competed at 155 for 20 YEARS… 1:17:05 How to Support Chandler 1:17:47 Ariel Helwani Set Up the Pod?! 1:18:47 DJ Praises Chandler 1:20:23 Mighty Recap! 1:21:02 DJ Reacts to Chandler's Time Off 1:23:09 Chandler Gets WAY Too Much Hate 1:29:34 McGregor's Anti-Wrestling Comments REACTION 1:31:33 Thoughts on UFC 309 1:32:42 DJ Doesn't Need to See Aspinall vs Jones? 1:35:52 Ranking the MMA Heavyweight Champs (Ngannou, Aspinall, and Jones) 1:37:21 Jones is Not One of the BEST Heavyweights Ever? Produced/Edited by Michael Wonsover (@mwonsover on IG/Twitter) Edited by Nick Pappas (@nick_pappas44 on IG)

Albeit for very different reasons, we've been looking forward to both Jon Jones vs. Stipe Miocic and Mike Tyson vs. Jake Paul for a while now. Both fights have experienced lengthy delays (one owing to Jones' torn pectoral, the other owing to Tyson “vomiting blood and defecating tar” on an airplane) and now they are going to share a single weekend. The spectacle that will be Tyson vs. Paul airs Friday night on Netflix, and perhaps even more than the fight itself, we're keen to see what the reaction will be on that platform. Jones and Miocic do the damn thing for the UFC heavyweight title the next night from Madison Square Garden in the main event of UFC 309. It'll be Jones' second foray into the big boy division, while Miocic returns for the first time since 2021. What will happen? Well, oddsmakers think they know. Is there any chance we might be surprised? Learn more about your ad choices. Visit megaphone.fm/adchoices

Sean and Graeme talk Jones vs. Stipe, Reug Reug, Oktagon, Prates, McGregor trial and more! And now….. here's the podcast!

Jason “Mayhem” Miller and Adam Carolla return to the audio octagon to discuss the week's latest mixed-martial arts news, including a potential “last dance” for Dustin Poirier, Conor McgGregor's legal troubles, what Chael Sonnen thinks Stipe has going for him against Jon Jones, and which fighter Tom Aspinall thinks could replace Dana White.

IS BO NICKAL THE FUTURE OF UFC?! On the latest episode of "MightyCast", Demetrious Johnson is joined by 3x NCAA champ & UFC top prospect Bo Nickal! Check Out Bo's Channel!  @nobickal1  If you're +21, try VIIA Hemp today and use code MIGHTY to save 15% https://bit.ly/viiamighty 0:00 Intro 0:57 Welcome Bo Nickal! 1:35 Bo is an ELITE Wrestler 2:34 Bo's Intro to Wrestling (Wrestling Prodigy) 6:57 Bo was Forced to Wrestle? 10:31 Going All In on Wrestling 12:49 VIIA Hemp! 14:05 The Importance of Playing Multiple Sports as a Kid 15:41 Did Bo Want to Go to the Olympics? 17:37 Bo's Dad Coaches Him?! 20:19 Hardest Part of the Transition from Wrestling to MMA 22:39 ATT Built Bo a Gym?! 26:16 Gordon Ryan vs Bo BREAKDOWN 31:51 MMA Fighters are Lazy? 33:27 Bo only had 1 Pro Fight Before the UFC?! 34:34 The Best Base for MMA 35:18 Bo's First Pro Fight 37:21 Winning TWICE on DWCS 39:09 Why Doesn't Bo Fight Very Often? 45:58 Bo's ELITE Training and Recovery Routines 49:03 Bo's UNIQUE Stretching Routine 52:17 Paul Craig vs Bo BREAKDOWN 57:22 Jon Jones vs Stipe Miocic BREAKDOWN 58:58 Intelligence in MMA is UNDERRATED 1:03:50 Where to Follow Bo 1:04:44 Bo is a New Father 1:08:35 Bo Got Paid by Penn State After College?! 1:13:09 Mighty Recap! 1:13:21 Bo is a True Competitor 1:14:54 Coaching Your Kids is HARD 1:15:35 DJ Reacts to Bo Taking Big Gaps Between Fights 1:16:19 Bo Nickal vs Paul Craig BREAKDOWN 1:18:21 Bo and DJ's Off-Air Conversation 1:19:55 Can Bo Become Champ at 185? Produced/Edited by Michael Wonsover (@mwonsover on IG/Twitter) Edited by Nick Pappas (@nick_pappas44 on IG) ⚡️ PrizePicks: Sign up with code "MIGHTYCAST" to play $5 and WIN $50 INSTANTLY https://prizepicks.onelink.me/ivHR/MIGHTYCAST If you're +21, try VIIA Hemp today and use code MIGHTY to save 15% https://bit.ly/viiamighty ⚡️ 1st Phorm: Check out 1st Phorm at https://1stphorm.com/mightycast ★ Merch: https://shopmighty.com ♦ Twitter: https://twitter.com/mightymouse/ ♦ Instagram: https://www.instagram.com/mighty/ ♦ Discord: https://discord.gg/mightysquad ♦ My Quantum Bars: https://quantumsquares.com/ Promo Code: MIGHTYGAMING10 ♦ My Cold Therapy: https://icebarrel.com/ Promo Code: MIGHTY

Where is Ryan Bader?! - FIS Ep.193 ft. PFL Heavyweight Daniel James "The American Predator"Daniel James TELLS ALL in this incredible interview, which details his recent USADA suspension, the PFL and Bellator's (mis) management of the situation, Timmy B's conspiracy theory around the whole thing (which is spot on), AND get a SNEAK PEEK at how Stipe's training is going, with the American Predator, ahead of #UFC309!PLUS: Ringside Raine and Timmy B discuss the bizarre flyweight title fight against a relative unknown at #UFC310 in lieu of fighting ANY ranked UFC flyweight?!?! Make it make sense, Dana!Get our merch at https://millions.co/fight-in-sight ! Look cooler than you do now.For sponsorship opportunities, to purchase our shirt/tank top, or to find out how you can be a guest on the show, please email us at fightinsightpod@gmail.comFinally, and most importantly, please follow, subscribe, leave a 5-star rating, and tell your friends about us!Guest LinksConnect with Ringside Raine: Instagram: https://www.instagram.com/ringsideraine/Connect with Daniel: Instagram: https://www.instagram.com/danieljames_predator/Follow Fight In SightFIGHT IN SIGHT IG: https://www.instagram.com/fightinsightpodcast/FIGHT IN SIGHT YouTube: https://www.youtube.com/channel/UC8ZW2w0va-VWeep_JtlhAjQExplore more from the Rage Works Podcast Network: https://www.rageworksnetwork.com/The views expressed on air during the Fight In Sight Podcast do not represent the views of the RAGE Works staff, partners, or affiliates. Listener discretion is advised.

The Big Mates discuss retrofuturism, The Amazing Spider-man, rude dealers, and Up by R.E.M.Adam, Steve, and Lucas continue their deep dive into the career and discography of R.E.M. by continuing their analysis of the band's eleventh studio album, released in 1998. They talk about the writing and recording process, the context surrounding the songs, and offer up analysis, opinions, and thoughts from three differing perspectives on music, from being deeply into analysis and music, to not caring for art or critique, and everything in between.They pick up their discussion near the beginning of the album and continue their trakc-by-track analysis, discussing mood, tone, co-writing credits, Stipe's new way of writing, and the band's goal of being "fearless."How far into the album will they get? How many Christmas songs are on the album? What have horses got to do with Westerns? Find out on this episode of What Is Music?Our next episode is out on Monday October 28th and will conclude our analysis of Up!Join the conversation on:Twitter: https://twitter.com/whatismusicpodInstagram: https://www.instagram.com/whatismusicpodE-mail: whatismusicpod@gmail.comGet access to more shows, exclusive bonus content, ad-free episodes of this show, and more music discussion by subscribing to our Patreon!Head to patreon.com/whatismusicpod and receive up to two new episodes of our various shows every week (including shows about Manic Street Preachers and monthly themed playlists!), ad-free archives of What Is Music?, and access to our Patron-only Discord server for even more music (and non-music) discussion!Support our show when starting your own podcast!By signing up to Buzzsprout with this link: https://www.buzzsprout.com/?referrer_id=780379Check out our merch!https://whatismusicpod.redbubble.comDonate to our podcast!https://ko-fi.com/whatismusichttp://whatismusic.buzzsprout.com/Support the show

On this episode of Good Guy / Bad Guy…It's official! Jon Jones will take on Stipe Miocic for the Heavyweight Title at Madison Square Garden this November. But this could likely be the last fight for both fighters. Does that mean they're afraid to lose to Interim Heavyweight Champ Tom Aspinall? Well, one of our guys seem to believe so. Plus, Dana White drops a bombshell that Charles Oliveira is next for Michael Chandler and NOT Conor McGregor. Is this a smart move for Michael Chandler and is it a wrap for Conor McGregor inside the octagon? And, DC visited Merab Dvalishvili at his home following his massive win over Sean O'Malley and explains why he really is “The Machine”. Learn more about your ad choices. Visit megaphone.fm/adchoices

Michael Bisping and Anthony Smith discuss all the action at UFC 305 from Dricus digging deep to find a submission win to what's next for Israel Adesanya, Alex Pereira offering to come back down to 185 to finish what Izzy started, Dan Hooker breaking back into the top 5, the controversial scorecard from the Jairzinho Rozenstruik vs Tai Tuiavasa fight before being joined by Brendan Loughnane to talk his upcoming PFL Semi-Final fight this weekend, what it was like growing up on the mean streets of Manchester, how long he plans to keep fighting and more then Tom Aspinall joins the show to talk his big win at UFC 304, why Jon Jones suddenly stopped saying his name, why he believes neither Jones nor Stipe will ever fight him and more plus Poatan vs Khalil Rountree at UFC 307, Brendan Allen and Marvin Vettori kicking off in a casino and so much more!This Episode Was Recorded On 08.19.24Support Our SponsorseBay Motors - http://ebaymotors.com Keep your ride-or-die alive with Ebay Motors!Mando - https://www.ShopMando.com get $5 off your Starter Pack (that's over 40% off) with promo code Bisping!Viia - https://viiahemp.com/ Use code Believe to get 15% off the rest you deserve!Believe You Me is available for early pre release on GaS Digital Network every Monday. Sign-up with code BYM to get access to the archives, bonus content and more! https://gasdigital.com/Follow the show on social media:Twitter: https://twitter.com/BYMPodSubscribe on YouTube: https://bit.ly/3drq6psFollow the hosts on social:Michael Bisping Twitter https://twitter.com/bispingMichael Bisping Instagram https://www.instagram.com/mikebisping/Michael Bisping YouTube https://www.youtube.com/channel/UCDrG2_1TcVkXKXXsD6KjwigWebsite https://gasdigitalnetwork.com/gdn-show-channels/believe-you-me/Anthony Smith Twitter: https://twitter.com/lionheartasmithAnthony Smith Instagram: https://www.instagram.com/lionheartasmith/Mike's debut book "Quitters Never Win" is available wherever books are sold, click here to get a copy! https://bit.ly/2V9ZqDkFollow The Guests On SocialTom Apinall Twitter: https://twitter.com/AspinallMMATom Apinall Instagram: https://www.instagram.com/tomaspinallofficialBrendan Loughnane Twitter: https://twitter.com/BrendanMMABrendan Loughnane Instagram: https://www.instagram.com/brendanmmaFollow the team on social:Brian MacKay Instagram: https://www.instagram.com/bmackayisrightBrian MacKay Twitter: https://twitter.com/bmackayisrightMike Harrington Twitter: https://twitter.com/TheMHarringtonMike Harrington Instagram https://www.instagram.com/themharringtonMike Harrington YouTube: https://www.youtube.com/@themharringtonBelieve You Me is a twice weekly podcast covering MMA news in a comedy podcast format hosted by former UFC Middleweight Champion Michael Bisping.Michael Bisping is a Former UFC Middleweight Champion. He transitioned to commentary in his post fight career and regularly calls the biggest fights. In addition to analyst work Michael has been cast in shows on Netflix, CBS and Showtime and has appeared in movies such as XXX: Return of Xander Cage, Den Of Thieves and Triple Threat. His next project slated for release is Warrior on Netflix in October, his self titled documentary "Bisping" is out now and just made #1 on the US and UK charts.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Michael Bisping and Anthony Smith talk UFC 305 fight week being here and all the storylines surrounding it from Israel Adesanya's much anticipated return to DDP getting tasered by his coach and saying Sean Strickland is going to be on the sidelines for a long time if he waits for a title shot, Merab taking aim at Tim Welch, the update to the unified rules of MMA to allow 12-6 Elbows, Tom Aspinall calling for Stipe to get the Joe Biden treatment and so much more!This Episode Was Recorded On 08.12.24Support Our SponsorsBetter Help - This episode is sponsored by Better Help. Visit https://www.betterhelp.com/Believe today to get 10% off your first month.eBay Motors - http://ebaymotors.com Keep your ride-or-die alive with Ebay Motors!Fit Bod - https://Fitbod.me/BELIEVE Click the link to sign up and get 25% off your subscription or try out the app for FREE True Nutrition - Truenutrition.com/believe Take the guesswork out of nutrition and get 15% off with code BelieveFollow the show on social media:Twitter: https://twitter.com/BYMPodSubscribe on YouTube: https://bit.ly/3drq6psFollow the hosts on social:Michael Bisping Twitter https://twitter.com/bispingMichael Bisping Instagram https://www.instagram.com/mikebisping/Michael Bisping YouTube https://www.youtube.com/channel/UCDrG2_1TcVkXKXXsD6KjwigWebsite https://gasdigitalnetwork.com/gdn-show-channels/believe-you-me/Anthony Smith Twitter: https://twitter.com/lionheartasmithAnthony Smith Instagram: https://www.instagram.com/lionheartasmith/Mike's debut book "Quitters Never Win" is available wherever books are sold, click here to get a copy! https://bit.ly/2V9ZqDkFollow the team on social:Brian MacKay Instagram: https://www.instagram.com/bmackayisrightBrian MacKay Twitter: https://twitter.com/bmackayisrightMike Harrington Twitter: https://twitter.com/TheMHarringtonMike Harrington Instagram https://www.instagram.com/themharringtonMike Harrington YouTube: https://www.youtube.com/@themharringtonBelieve You Me is a twice weekly podcast covering MMA news in a comedy podcast format hosted by former UFC Middleweight Champion Michael Bisping.Michael Bisping is a Former UFC Middleweight Champion. He transitioned to commentary in his post fight career and regularly calls the biggest fights. In addition to analyst work Michael has been cast in shows on Netflix, CBS and Showtime and has appeared in movies such as XXX: Return of Xander Cage, Den Of Thieves and Triple Threat. His next project slated for release is Warrior on Netflix in October, his self titled documentary "Bisping" is out now and just made #1 on the US and UK charts.“To advertise your product on GaS Digital podcasts please email jimmy@gasdigitalmarketing.com with a brief description about your product and any shows you may be interested in advertising on”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The UFC this week made good on its promise to book a men's featherweight title fight between Ilia Topuria and Max Holloway and we … are … stoked. For hardcore fans, this might be the best fight available right now (if we're really going through with Jones vs. Stipe instead of Jones vs. Aspinall) and actually getting it is cause for celebration. It's going down at UFC 308 in October. Only question is, will Holloway's BMF belt be on the line, too, or are we finally admitting the BMF title is just some shit we hand out to whoever, whenever it fits our needs? Plus, Dana White would like us to believe the judge denying the settlement in the UFC antitrust lawsuit is rooted in some high school bullshit and Conor McGregor showed up to cosplay at Stugis of all goddamned places. Learn more about your ad choices. Visit megaphone.fm/adchoices

Nate Diaz and Jorge Masvidal wrote the second chapter of their combat sports rivalry this past Saturday night in the boxing ring. This time, Diaz got the victory over Masvidal in a very fun 10-rounder. How do you grade the fight between one-time UFC competitors, and what is next for both guys? On an all-new edition of Between the Links, the MMA Fighting panel reacts to the Diaz vs. Masvidal fight, if a third meeting should be next, and how likely Diaz and Masvidal's next fights will be in the UFC. Additionally, topics include this Saturday's UFC Denver event, the headliner between former champ Rose Namajunas and Tracy Cortez and the stakes for both women, other must-see bouts on the card, Jon Jones and Stipe Miocic continuing to defend their potential fight, Darren Till's boxing debut, and more. Host Mike Heck moderates the matchup between MMA Fighting's Jed Meshew and Alexander K. Lee.  Follow Mike Heck: @MikeHeck_JR Follow Jed Meshew: @JedKMeshew Follow Alexander K. Lee: @AlexanderKLee Subscribe to MMA Fighting Check out our full video catalog Like MMA Fighting on Facebook Follow on Twitter Read More: http://www.mmafighting.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Nate Diaz and Jorge Masvidal wrote the second chapter of their combat sports rivalry this past Saturday night in the boxing ring. This time, Diaz got the victory over Masvidal in a very fun 10-rounder. How do you grade the fight between one-time UFC competitors, and what is next for both guys? On an all-new edition of Between the Links, the MMA Fighting panel reacts to the Diaz vs. Masvidal fight, if a third meeting should be next, and how likely Diaz and Masvidal's next fights will be in the UFC. Additionally, topics include this Saturday's UFC Denver event, the headliner between former champ Rose Namajunas and Tracy Cortez and the stakes for both women, other must-see bouts on the card, Jon Jones and Stipe Miocic continuing to defend their potential fight, Darren Till's boxing debut, and more. Host Mike Heck moderates the matchup between MMA Fighting's Jed Meshew and Alexander K. Lee.  Follow Mike Heck: @MikeHeck_JR Follow Jed Meshew: @JedKMeshew Follow Alexander K. Lee: @AlexanderKLee Subscribe to MMA Fighting Check out our full video catalog Like MMA Fighting on Facebook Follow on Twitter Read More: http://www.mmafighting.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Well, you know what they say about sunshine and the proverbial dog's ass. Hard to believe, but Nate Diaz and Jorge Masvidal went out there and had an (allegedly) entertaining boxing match over the weekend. We guess the law of averages says it was bound to happen eventually. Question is, though, now that we're this far down the road into the overwhelmingly disappointing “old MMA guys try to box” period of our declining society, did anybody watch? Plus, Jon Jones says he and Stipe finally have something on the books and Reug Reug wins a fight against a guy named Ketchup that was even more ridiculous than it sounds. Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode of Good Guy / Bad Guy... Joaquin Buckley won in front of his home crowd this past weekend and followed that up by calling out Conor. McGregor. How bad did Buckley fumble his opportunity? Also, 1 month removed from UFC 300, does Max Holloway's KO still hold up in their minds as the greatest knockout of all time? Plus, Chael & DC goes 5 Rounds... Should Jones be focusing solely on Stipe? Can Carlos Ulberg make a run at light heavyweight? And the bad guy made his MMA debut 27 years ago this week! We look back on that historic moment. Learn more about your ad choices. Visit megaphone.fm/adchoices

Michael Bisping and Anthony Smith discuss Anthony's big win at UFC 301 over Vitor Petrino, responding to getting called out for a submission challenge by Alex Pereira getting offered a super quick turn around fight and more plus a breakdown of Jose Aldo's triumphant return and the rest of the fights on the card, Conor calling out Ryan Garcia and Sean O'Malley for PED use, Jon Jones teasing a fight against Alex Periera instead of Tom Aspinall if all goes right in the Stipe fight, Big Tom's response and so much more!This Episode Was Recorded On 05.07.24Support Our SponsorsBetter Help - This episode is sponsored by Better Help. Visit https://www.BetterHelp.com/Believe today to get 10% off your first month.Eight Sleep - eightsleep.com/bisping Click The Link and get $200 off plus free shipping on the Pod CoverMando - https://www.ShopMando.com get $5 off your Starter Pack (that's over 40% off) with promo code Bisping!Believe You Me is available for early pre release on GaS Digital Network every Monday. Sign-up with code BYM to get access to the archives, bonus content and more! https://gasdigital.com/"Free Cain" Shirts Herehttps://derekbrunson.com/collections/mensFollow the show on social media:Twitter: https://twitter.com/BYMPodSubscribe on YouTube: https://bit.ly/3drq6psFollow the hosts on social:Michael Bisping Twitter https://twitter.com/bispingMichael Bisping Instagram https://www.instagram.com/mikebisping/Michael Bisping YouTube https://www.youtube.com/channel/UCDrG2_1TcVkXKXXsD6KjwigWebsite https://gasdigitalnetwork.com/gdn-show-channels/believe-you-me/Anthony Smith Twitter: https://twitter.com/lionheartasmithAnthony Smith Instagram: https://www.instagram.com/lionheartasmith/Mike's debut book "Quitters Never Win" is available wherever books are sold, click here to get a copy! https://bit.ly/2V9ZqDkFollow the team on social:Brian MacKay Instagram: https://www.instagram.com/bmackayisrightBrian MacKay Twitter: https://twitter.com/bmackayisrightMike Harrington Twitter: https://twitter.com/TheMHarringtonMike Harrington Instagram https://www.instagram.com/themharringtonMike Harrington YouTube: https://www.youtube.com/@themharringtonBelieve You Me is a twice weekly podcast covering MMA news in a comedy podcast format hosted by former UFC Middleweight Champion Michael Bisping.Michael Bisping is a Former UFC Middleweight Champion. He transitioned to commentary in his post fight career and regularly calls the biggest fights. In addition to analyst work Michael has been cast in shows on Netflix, CBS and Showtime and has appeared in movies such as XXX: Return of Xander Cage, Den Of Thieves and Triple Threat. His next project slated for release is Warrior on Netflix in October, his self titled documentary "Bisping" is out now and just made #1 on the US and UK charts.“To advertise your product on GaS Digital podcasts please email jimmy@gasdigitalmarketing.com with a brief description about your product and any shows you may be interested in advertising on”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Michael Bisping talks with Jon Anik about the pair calling UFC 298 together this weekend, Volkanovski vowing to humble Ilia Toupouria while poking fun at himself, Jon Jones drunkenly heckling at a comedy show, Jones talking about sticking around after his Stipe fight, more rumors for UFC 300 and more plus a recap of UFC Vegas 86, Sean Strickland looking to fight any influencer in sight, Henry Cejudo firing his coach on UFC Countdown and so much more!This Episode Was Recorded On 2.12.24Support Our SponsorsBetter Help - This episode is sponsored by Better Help. Visit https://www.BetterHelp.com/Believe today to get 10% off your first month.Tushy - https://hellotushy.com/BISPING - Get 10% off with the code BISPING at #tushypodFit Bod - https://Fitbod.me/BELIEVE Click the link to sign up and get 25% off your subscription or try out the app for FREEBelieve You Me is available for early pre release on GaS Digital Network every Monday and Thursday. Sign-up with code BYM to get access to the archives, bonus content and more! https://gasdigital.com/"Free Cain" Shirts Herehttps://derekbrunson.com/collections/mensFollow the show on social media:Twitter: https://twitter.com/BYMPodSubscribe on YouTube: https://bit.ly/3drq6psFollow the hosts on social:Michael Bisping Twitter https://twitter.com/bispingMichael Bisping Instagram https://www.instagram.com/mikebisping/Michael Bisping YouTube https://www.youtube.com/channel/UCDrG2_1TcVkXKXXsD6KjwigWebsite https://gasdigitalnetwork.com/gdn-show-channels/believe-you-me/Mike's debut book "Quitters Never Win" is available wherever books are sold, click here to get a copy! https://bit.ly/2V9ZqDkAnthony Smith Twitter: https://twitter.com/lionheartasmithAnthony Smith Instagram: https://www.instagram.com/lionheartasmith/Follow the team on social:Brian MacKay Instagram: https://www.instagram.com/bmackayisrightBrian MacKay Twitter: https://twitter.com/bmackayisrightFollow The Guest on social: Jon Anik Twitter: https://twitter.com/Jon_AnikJon Anik Instagram: https://www.instagram.com/jon_anik/Mike Harrington Twitter: https://twitter.com/TheMHarringtonMike Harrington Instagram https://www.instagram.com/themharringtonBelieve You Me is a twice weekly podcast covering MMA news in a comedy podcast format hosted by former UFC Middleweight Champion Michael Bisping.Michael Bisping is a Former UFC Middleweight Champion. He transitioned to commentary in his post fight career and regularly calls the biggest fights. In addition to analyst work Michael has been cast in shows on Netflix, CBS and Showtime and has appeared in movies such as XXX: Return of Xander Cage, Den Of Thieves and Triple Threat. His next project slated for release is Warrior on Netflix in October, his self titled documentary "Bisping" is out now and just made #1 on the US and UK charts.“To advertise your product on GaS Digital podcasts please email jimmy@gasdigitalmarketing.com with a brief description about your product and any shows you may be interested in advertising on”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Daniel Cormier is BACK to talk the BIGGEST headlines in the MMA world: Sean Strickland posting about taking a headbutt from Dricus Du Plessis in his loss at UFC 297, Jon Jones calling out DC last week, and Tom Aspinall confirming he accepted a Stipe Miocic fight at UFC 300. Don't miss Cormier CLAPPING BACK at Jon Jones and dismissing any rivalry with him. Plus, DC explains why despite Dana White saying Strickland won, Du Plessis was still the rightful winner. And DC reveals why Stipe Miocic could care less about a fight with Tom Aspinall. 3:40 - DC response to Jon Jones comments9:15 - Tom Aspinall wanted Stipe at UFC 30012:25 - Sean Strickland got headbutt by Dricus? #Volume #HerdSee omnystudio.com/listener for privacy information.

Michael Bisping and Kenny Florian discuss Kayla Harrison signing to fight at UFC 300 against Holly Holm, what it means for the division, and the blockbuster matchups it could setup, Tom Aspinall saying that he was offered a fight with Stipe at 300 but Stipe turned it down, Jon Anik thinking about quitting MMA broadcasting as a result of the negativity of the fanbase and more then the boys react to Conor McGregor's acting debut in the Road House remake, Khamzat demanding the title shot he was promised, Izzy releasing footage training boxing in Mexico and so much more!This Episode Was Recorded On 1.25.24Support Our SponsorsBetter Help - This episode is sponsored by Better Help. Visit https://www.BetterHelp.com/Believe today to get 10% off your first month.Shopify - https://www.shopify.com/believe Follow the link (all lower case) for a 2 week free trial of the No.1 eCommerce platform for all businessesPrize Picks - PrizePicks.com/believe - Click the link and use code believe for a first deposit match up to $100!Believe You Me is available for early pre release on GaS Digital Network every Monday and Thursday. Sign-up with code BYM to get access to the archives, bonus content and more! https://gasdigital.com/"Free Cain" Shirts Herehttps://derekbrunson.com/collections/mensFollow the show on social media:Twitter: https://twitter.com/BYMPodSubscribe on YouTube: https://bit.ly/3drq6psFollow the hosts on social:Michael Bisping Twitter https://twitter.com/bispingMichael Bisping Instagram https://www.instagram.com/mikebisping/Michael Bisping YouTube https://www.youtube.com/channel/UCDrG2_1TcVkXKXXsD6KjwigWebsite https://gasdigitalnetwork.com/gdn-show-channels/believe-you-me/Mike's debut book "Quitters Never Win" is available wherever books are sold, click here to get a copy! https://bit.ly/2V9ZqDkAnthony Smith Twitter: https://twitter.com/lionheartasmithAnthony Smith Instagram: https://www.instagram.com/lionheartasmith/Follow The Guest on social: Kenny Florian Twitter: https://twitter.com/kennyflorianKenny Florian Instagram: https://www.instagram.com/kennyflorian/Follow the team on social:Brian MacKay Instagram: https://www.instagram.com/bmackayisrightBrian MacKay Twitter: https://twitter.com/bmackayisrightMike Harrington Twitter: https://twitter.com/TheMHarringtonMike Harrington Instagram https://www.instagram.com/themharringtonBelieve You Me is a twice weekly podcast covering MMA news in a comedy podcast format hosted by former UFC Middleweight Champion Michael Bisping.Michael Bisping is a Former UFC Middleweight Champion. He transitioned to commentary in his post fight career and regularly calls the biggest fights. In addition to analyst work Michael has been cast in shows on Netflix, CBS and Showtime and has appeared in movies such as XXX: Return of Xander Cage, Den Of Thieves and Triple Threat. His next project slated for release is Warrior on Netflix in October, his self titled documentary "Bisping" is out now and just made #1 on the US and UK charts.“To advertise your product on GaS Digital podcasts please email jimmy@gasdigitalmarketing.com with a brief description about your product and any shows you may be interested in advertising on”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Michael Bisping and Anthony Smith talk everything UFC 297 from the controversial split decision win for Dricus Du Plesis to Sean Strickland claiming the damage to his eye was caused by a headbutt, Ian Garry calling both men sloppy in a reaction video, Raquel Pennington achieving a dream ten years in the making by winning the title, Neil Magny getting a win for the veterans at the hands of Mike Malott and more plus Conor likely won't be back for international fight week but Jones vs Stipe could take place over the summer and so much more!This Episode Was Recorded On 1.22.24Support Our SponsorsChoq - https://choq.com/ - Use promo code BISPING for 35% off your order!Eight Sleep - eightsleep.com/bisping and get $200 off plus free shipping on the Pod CoverFit Bod - https://Fitbod.me/BELIEVE Click the link to sign up and get 25% off your subscription or try out the app for FREEBelieve You Me is available for early pre release on GaS Digital Network every Monday and Thursday. Sign-up with code BYM to get access to the archives, bonus content and more! https://gasdigital.com/"Free Cain" Shirts Herehttps://derekbrunson.com/collections/mensFollow the show on social media:Twitter: https://twitter.com/BYMPodSubscribe on YouTube: https://bit.ly/3drq6psFollow the hosts on social:Michael Bisping Twitter https://twitter.com/bispingMichael Bisping Instagram https://www.instagram.com/mikebisping/Michael Bisping YouTube https://www.youtube.com/channel/UCDrG2_1TcVkXKXXsD6KjwigWebsite https://gasdigitalnetwork.com/gdn-show-channels/believe-you-me/Mike's debut book "Quitters Never Win" is available wherever books are sold, click here to get a copy! https://bit.ly/2V9ZqDkAnthony Smith Twitter: https://twitter.com/lionheartasmithAnthony Smith Instagram: https://www.instagram.com/lionheartasmith/Follow the team on social:Brian MacKay Instagram: https://www.instagram.com/bmackayisrightBrian MacKay Twitter: https://twitter.com/bmackayisrightMike Harrington Twitter: https://twitter.com/TheMHarringtonMike Harrington Instagram https://www.instagram.com/themharringtonBelieve You Me is a twice weekly podcast covering MMA news in a comedy podcast format hosted by former UFC Middleweight Champion Michael Bisping.Michael Bisping is a Former UFC Middleweight Champion. He transitioned to commentary in his post fight career and regularly calls the biggest fights. In addition to analyst work Michael has been cast in shows on Netflix, CBS and Showtime and has appeared in movies such as XXX: Return of Xander Cage, Den Of Thieves and Triple Threat. His next project slated for release is Warrior on Netflix in October, his self titled documentary "Bisping" is out now and just made #1 on the US and UK charts.“To advertise your product on GaS Digital podcasts please email jimmy@gasdigitalmarketing.com with a brief description about your product and any shows you may be interested in advertising on”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.